Drug Profile

X4P 002

Alternative Names: X4P-002

Latest Information Update: 24 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator X4 Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action CXCR4 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Suspended Glioblastoma

Most Recent Events

31 Dec 2023 X4 Pharmaceuticals has patents pending for X4P 002 in USA and globally, prior to December 2023
31 Dec 2023 X4 Pharmaceuticals has patent protection for X4P 002 in the US, prior to December 2023
12 Apr 2023 Suspended - Preclinical for Glioblastoma in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com